Brexafemme

Chemical Nameibrexafungerp
Dosage FormTablet (oral; 150 mg)
Drug ClassAntifungals
SystemFemale reproductive
CompanySCYNEXIS
Approval Year2021

Indication

  • For the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC)
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Brexafemme (ibrexafungerp tablets) Prescribing Information.2021SCYNEXIS Inc., Jersey City, NJ